Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Otsuka Discontinues Development of Amsilarotene
June 7, 2010
- Astellas, NBI Extend Marketing Agreement for Micardis
June 7, 2010
- Favorable PII Results Obtained with Riociguat for Pulmonary Hypertension
June 7, 2010
- NanoCarrier Obtains Substance Patent Related to Polymer Micelles
June 7, 2010
- Sanofi-aventis Begins Large-Scale Study with Multaq in Permanent AF
June 7, 2010
- Eisai Opens New Oncology Drug Production Facility in the US
June 7, 2010
- New GL for Osteoporosis to Reflect Results of JOINT-02 Study
June 7, 2010
- Finished Drug Products Show Largest Production in 10 Years in FY2008
June 7, 2010
- NEW PRODUCTS
June 7, 2010
- Market for Hypotensives to Expand to \1 Tril. in 2018: Fuji-Keizai
June 7, 2010
- Sanofi-aventis Aims at Top-5 Position in 5 Years in Japan: CEO C. Viehbacher
June 7, 2010
- 5 APIs See 1st Generics Listed
June 7, 2010
- Daiichi Sankyo to Insist on Achieving Numerical Goals: New President Nakayama
June 7, 2010
- Incentives for Use of Generics Boost Business of JGA Member Companies
June 7, 2010
- Astellas Aims at Sales of ¥1,100 Bil. In FY2014
June 7, 2010
- Meiji Seika: Pharm. Business Driven by Generics
June 7, 2010
- Women Receives Cervarix at 31.4 of Age on Average in Japan: GSK
June 7, 2010
- Teijin Pharma to Increase No. of MRs to Market TMX-67
June 7, 2010
- Zeria Aims at Overseas Sales Ratio of >25%: President Ibe
June 7, 2010
- Major New Entrants in Generics Market, Emergence of AGs
June 7, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…